Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AR-42

Last Updated: 02/16/18

Status: Unknown


Chemical Structure, AR42

Synonyms: AR42, OSU-HDAR42, HDAR42,
N-hydroxy-4-(3-methyl-2-phenylbutyrylamino)benzamide
Pharmaceutical Company: Arno Therapeutics
Legal Status: ℞ - Prescription/Under Clinical Trial
Administered By: Pill - Oral
Tumor Target: Meningioma and Schwannoma
Protein Target: HDACi Inhibitor
NF2 Trials Recruiting Trial: NCT02282917
Formula: C18 H20 N2 O3
Chemical Name: (S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide

Other Uses

Complete list of other health issues Ohio State University Comprehensive Cancer Center is testing AR-42 on.




NF2 Related Trials

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

ClinicalTrials.gov NCT01129193

Phase 1

  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Cutaneous B-cell Non-Hodgkin Lymphoma
  • Extranodal Marginal Zone B-cell Lymphoma of
    Mucosa-associated Lymphoid Tissue
  • Hepatosplenic T-cell Lymphoma
  • Intraocular Lymphoma
  • Nodal Marginal Zone B-cell Lymphoma
  • Peripheral T-cell Lymphoma
  • Post-transplant Lymphoproliferative Disorder
  • Prolymphocytic Leukemia
  • Recurrent Adult Burkitt Lymphoma
  • Recurrent Adult Diffuse Large Cell Lymphoma
  • Recurrent Adult Diffuse Mixed Cell Lymphoma
  • Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
  • Recurrent Adult Grade III Lymphomatoid Granulomatosis
  • Recurrent Adult Hodgkin Lymphoma
  • Recurrent Adult Immunoblastic Large Cell Lymphoma
  • Recurrent Adult Lymphoblastic Lymphoma
  • Recurrent Adult T-cell Leukemia/Lymphoma
  • Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
  • Recurrent Grade 1 Follicular Lymphoma
  • Recurrent Grade 2 Follicular Lymphoma
  • Recurrent Grade 3 Follicular Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Marginal Zone Lymphoma
  • Recurrent Mycosis Fungoides/Sezary Syndrome
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Multiple Myeloma
  • Stage III Adult Burkitt Lymphoma
  • Stage III Adult Diffuse Large Cell Lymphoma
  • Stage III Adult Diffuse Mixed Cell Lymphoma
  • Stage III Adult Diffuse Small Cleaved Cell Lymphoma
  • Stage III Adult Hodgkin Lymphoma
  • Stage III Adult Immunoblastic Large Cell Lymphoma
  • Stage III Adult Lymphoblastic Lymphoma
  • Stage III Adult T-cell Leukemia/Lymphoma
  • Stage III Chronic Lymphocytic Leukemia
  • Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage III Grade 1 Follicular Lymphoma
  • Stage III Grade 2 Follicular Lymphoma
  • Stage III Grade 3 Follicular Lymphoma
  • Stage III Mantle Cell Lymphoma
  • Stage III Marginal Zone Lymphoma
  • Stage III Multiple Myeloma
  • Stage III Mycosis Fungoides/Sezary Syndrome
  • Stage III Small Lymphocytic Lymphoma
  • Stage IV Adult Burkitt Lymphoma
  • Stage IV Adult Diffuse Large Cell Lymphoma
  • Stage IV Adult Diffuse Mixed Cell Lymphoma
  • Stage IV Adult Diffuse Small Cleaved Cell Lymphoma
  • Stage IV Adult Hodgkin Lymphoma
  • Stage IV Adult Immunoblastic Large Cell Lymphoma
  • Stage IV Adult Lymphoblastic Lymphoma
  • Stage IV Adult T-cell Leukemia/Lymphoma
  • Stage IV Chronic Lymphocytic Leukemia
  • Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
  • Stage IV Grade 1 Follicular Lymphoma
  • Stage IV Grade 2 Follicular Lymphoma
  • Stage IV Grade 3 Follicular Lymphoma
  • Stage IV Mantle Cell Lymphoma
  • Stage IV Marginal Zone Lymphoma
  • Stage IV Mycosis Fungoides/Sezary Syndrome
  • Stage IV Small Lymphocytic Lymphoma
  • Testicular Lymphoma
  • Waldenstrom Macroglobulinemia

Sources

  • Burns, S. S., Akhmametyeva, E. M., Oblinger, J. L., Bush, M. L., Huang, J., Senner, V., ... & Chang, L. S. (2013). "Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting NF2-Deficient Meningioma Growth." Cancer Research, 73(2), 792-803.
    Source: http://cancerres.aacrjournals.org/content/73/2/792.short | DOI: 10.1158/0008-5472.CAN-12-1888

  • Wang, G. H., Jiang, F. Q., Duan, Y. H., Zeng, Z. P., Chen, F., Dai, Y., ... & Zhang, X. K. (2013). "Targeting Truncated Retinoid X Receptor-a by CF31 Induces TNF-a-Dependent Apoptosis." Cancer research, 73(1), 307-318.
    Source: http://cancerres.aacrjournals.org/content/73/1/307.short

  • Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A. "AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.." Neuro-Oncology. Vol. 13, no. 9. (September 2011.): 983-.
    http://neuro-oncology.oxfordjournals.org/content/13/9/983.short]

  • Xu, Weihong, et al. "The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production." Biochemical and biophysical research communications 463.4 (2015): 545-550.
  • CSID: 5293992, http://www.chemspider.com/Chemical-Structure.5293992.html (accessed 20:22, Nov 19, 2017)
  • "Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead." MedChemCom (2015) DOI: 10.1039/C5MD00247H